Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Tumour biomarkers

A mark is a marker

Early detection of cancer is crucial to improve prognosis, and circulating tumour DNA (ctDNA) presents a minimally invasive screening tool. In contrast to mutation patterns, DNA methylation patterns in ctDNA resemble that of cancer tissue. Xu et al. showed that ctDNA methylation patterns can be used as biomarkers for diagnosis and prediction in hepatocellular carcinoma (HCC). Through analysis of differential methylation profiles in HCC tissues and blood leukocytes in healthy individuals, they identified a panel of methylation markers enriched in HCC. They successfully validated this panel in matched DNA from HCC tumour tissue and plasma. Using ctDNA from a cohort of 1,098 patients with HCC and 835 normal controls, the researchers developed diagnostic and prognostic prediction models. These models strongly correlated with tumour burden, stage and therapy response, and reliably predicted clinical outcomes.


  1. 1

    Xu, R. et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater. (2017)

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Harjes, U. A mark is a marker. Nat Rev Cancer 17, 708 (2017).

Download citation


Quick links